Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV) von DeVincenzo, John, Cehelsky, Jeffrey E., Alvarez, Rene, Elbashir, Sayda, Harborth, Jens, Toudjarska, Iva, Nechev, Lubomir, Murugaiah, Veeravagu, Vliet, Andre Van, Vaishnaw, Akshay K., Meyers, Rachel

Volltext

Phase 1 Trial of an RNA Interference Therapy for Acute Intermittent Porphyria von Sardh, Eliane, Harper, Pauline, Balwani, Manisha, Stein, Penelope, Rees, David, Bissell, D. Montgomery, Desnick, Robert, Parker, Charles, Phillips, John, Bonkovsky, Herbert L, Vassiliou, Daphne, Penz, Craig, Chan-Daniels, Amy, He, Qiuling, Querbes, William, Fitzgerald, Kevin, Kim, Jae B, Garg, Pushkal, Vaishnaw, Akshay, Simon, Amy R, Anderson, Karl E

Volltext

Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy von Pasi, K. John, Rangarajan, Savita, Georgiev, Pencho, Mant, Tim, Creagh, Michael D, Lissitchkov, Toshko, Bevan, David, Austin, Steve, Hay, Charles R, Hegemann, Inga, Kazmi, Rashid, Chowdary, Pratima, Gercheva-Kyuchukova, Liana, Mamonov, Vasily, Timofeeva, Margarita, Soh, Chang-Heok, Garg, Pushkal, Vaishnaw, Akshay, Akinc, Akin, Sørensen, Benny, Ragni, Margaret V

Volltext

The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis von Straus, Stephen E., Jaffe, Elaine S., Puck, Jennifer M., Dale, Janet K., Elkon, Keith B., Rösen-Wolff, Angela, Peters, Anke M.J., Sneller, Michael C., Hallahan, Claire W., Wang, Jin, Fischer, Roxanne E., Jackson, Christine M., Lin, Albert Y., Bäumler, Caroline, Siegert, Elke, Marx, Alexander, Vaishnaw, Akshay K., Grodzicky, Tamara, Fleisher, Thomas A., Lenardo, Michael J.

Volltext

Fas Gene Mutations in the Canale–Smith Syndrome, an Inherited Lymphoproliferative Disorder Associated with Autoimmunity von Drappa, Jörn, Vaishnaw, Akshay K, Sullivan, Kathleen E, Chu, Jia-Li, Elkon, Keith B

Volltext

The molecular basis for apoptotic defects in patients with CD95 (Fas/Apo-1) mutations von Vaishnaw, A K, Orlinick, J R, Chu, J L, Krammer, P H, Chao, M V, Elkon, K B

Volltext

41: Results of a Randomized Phase 2 Trial of ALN-RSV01, an RNAi Therapeutic, Lung Transplant (LTX) Patients Infected with Respiratory Syncytial Virus (RSV) von Zamora, M.R, Budev, M, Rolfe, M, Gottlieb, J, DeVincenzo, J, Cehelsky, J, Albert, G, Gollob, J, Nochur, S, Vaishnaw, A, Glanville, A

Volltext

Development of a Human Experimental Infection Model of Respiratory Syncytial Virus (RSV) and Evaluation of an RNA Interference (RNAi) Therapeutic for Safety and Anti-Viral Efficacy... von DeVincenzo, J, Lambkin-Williams, R, Cehelsky, J, Wilkinson, T, Obute, O, Foote, K, Nochur, S, Gilberts, A, Mann, A, Moane, E, Walsh, E, Studholme, B, Dorset, P, Oxford, J, Meyers, R, Vaishnaw, A

Volltext

Phase 2 open-label extension study (ole) of patisiran, an investigational sIRNA investigational agent for familial amyloid polyneuropathy (fap) von Coelho, T., Suhr, Ole, Conceicao, I, Waddington-Cruz, M., Schmidt, H., Buades, J., Campistol, J., Pouget, J., Berk, J., Falzone, R., White, L., Bettencourt, B., Cehelsky, J., Nochur, S., Vaishnaw, A., Gollob, J., Adams, D.

Volltext

Interim safety and pharmacodynamic results for ALN-VSP02, a novel RNAi therapeutic for solid tumors with liver involvement von Gollob, J., Infante, J. R., Shapiro, G., LoRusso, P., Dezube, B. J., Heymach, J., Cehelsky, J., Falzone, R., Vaishnaw, A., Burris, H. A.

Volltext

Regulation of Transcription of the TATA-less Human Complement Component C4 Gene von Vaishnaw, Akshay K, Mitchell, Tracey J, Rose, S. Jane, Walport, Mark J, Morley, Bernard J

Volltext

Phase I dose-escalation study of ALN-VSP02, a novel RNAi therapeutic for solid tumors with liver involvement von Cervantes, A., Alsina, M., Tabernero, J., Infante, J. R., LoRusso, P., Shapiro, G., Paz-Ares, L. G., Falzone, R., Hill, J., Cehelsky, J., White, A., Toudjarska, I., Bumcrot, D., Meyers, R., Hinkle, G., Svrzikapa, N., Sah, D. W., Vaishnaw, A., Gollob, J., Burris, H. A.

Volltext

Interim results from phase ii trial of aln-ttr02, a novel RNAi therapeutic for the treatment of familial amyloidotic polyneuropathy von Adams, D., Coelho, T., Suhr, Ole, Conceicao, I., Waddington-Cruz, M., Schmidt, H., Campistol, J., Pouget, J., Buades, J., Falzone, R., Harrop, J., De Frutos, R., Butler, J., Cehelsky, J., Nochur, S., Vaishnaw, A., Gollob, J.

Volltext

Apoptosis in the rheumatic diseases von Vaishnaw, Akshay K., McNally, Jeremy D., Elkon, Keith B.

Volltext

CD4 + T-cell–directed antibody responses are maintained in patients with psoriasis receiving alefacept: results of a randomized study von Gottlieb, Alice B, Casale, Thomas B, Frankel, Ellen, Goffe, Bernard, Lowe, Nicholas, Ochs, Hans D, Roberts, Janet L, Washenik, Ken, Vaishnaw, Akshay K, Gordon, Kenneth B

Volltext

The spectrum of apoptotic defects and clinical manifestations, including systemic lupus erythematosus, in humans with CD95 (Fas/APO‐1) mutations von Vaishnaw, Akshay K., Toubi, Elias, Ohsako, Satomi, Drappa, Jorn, Buys, Saundra, Estrada, Jaime, Sitarz, Anneliese, Zemel, Larry, Chu, Jia‐Li, Elkon, Keith B.

Volltext

Requirement of Cysteine-rich Repeats of the Fas Receptor for Binding by the Fas Ligand von Orlinick, Jason R., Vaishnaw, Akshay, Elkon, Keith B., Chao, Moses V.

Volltext

Structure and Function of Fas/Fas Ligand von Orlinick, Jason R., Vaishnaw, Akshay K., Elkon, Keith B.

Volltext

Pharmacokinetics, biologic activity, and tolerability of alefacept by intravenous and intramuscular administration von VAISHNAW, Ashay K, TENHOOR, Christopher N

Volltext

DNase I hypersensitivity mapping and promoter polymorphism analysis of human C4 von Vaishnaw, A K, Hargreaves, R, Campbell, R D, Morley, B J, Walport, M J

Volltext